SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting and stringent CARF ribonuclease activation.
Steens JA, Zhu Y, Taylor DW, Bravo JPK, Prinsen SHP, Schoen CD, Keijser BJF, Ossendrijver M, Hofstra LM, Brouns SJJ, Shinkai A, van der Oost J, Staals RHJ.
Steens JA, et al. Among authors: bravo jpk.
Nat Commun. 2021 Aug 19;12(1):5033. doi: 10.1038/s41467-021-25337-5.
Nat Commun. 2021.
PMID: 34413302
Free PMC article.